BROSSARD, Quebec, April 06, 2018 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces the disposal of 10,500,000 common shares (“Shares”) of Albert Mining Inc. (“Albert” or the “Issuer”), formerly Majescor Resources Inc. (“Majescor”).
The Shares were acquired as follows; 2,500,000 Shares as payment for services rendered to Majescor and 8,000,000 Shares as payment for the sale of the assets from the Corporation’s mining division to Majescor (refer to the May 17th, 2017 news release for more information). DIAGNOS has decided to sell the Shares due to its divestiture from the mining sector, as initially announced in a news release dated May 31st, 2017.
Immediately prior to the disposal of the Shares, DIAGNOS owned 10,500,000 Shares of the Issuer representing approximatively 16.6% of the outstanding Shares on an undiluted basis. Immediately following the disposal of 10,500,000 Shares, DIAGNOS does not own any Share of Albert. The disposal of the Shares triggered the requirement to file an early warning report (“Form 62-103F1”) and to publish this press release.
A copy of Form 62-103F1 can be found on SEDAR.com or may be obtained by submitting a written request to: Diagnos Inc., c/o Accounting and Legal Dept., 7005 Taschereau Blvd, suite 340, Brossard, Qc, J4Z 1A7, 450-678-8882.
About DIAGNOS and its technologies
DIAGNOS has developed CARA (Computer Assisted Retinal Analysis), a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises; image upload, image enhancement, automated pre-screening, grading by a specialist, and referral to a specialist. Based on our FLAIRE technology, CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and others.
For further information, please contact:
|Mr. Marc-André Massue, CFO|
|Tel: 450-678-8882 ext. 235|
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.